循环肿瘤细胞在转移性乳腺癌中的表达及其与多种血清肿瘤标志物的关系

doi:10.3969/j.issn.1002-3070.2012.03.007

实用肿瘤学杂志 ›› 2012, Vol. 26 ›› Issue (3): 220-224.doi: 10.3969/j.issn.1002-3070.2012.03.007

循环肿瘤细胞在转移性乳腺癌中的表达及其与多种血清肿瘤标志物的关系

钱六七¹, 刘芊², 刘毅³, 张少华², 王涛², 吴世凯², 宋三泰², 刘兵³, 江泽飞¹

1.安徽医科大学解放军307临床学院乳腺肿瘤科(北京 100071);
2.解放军307医院乳腺肿瘤科;
3.解放军307医院肿瘤学研究室

收稿日期:2012-02-03 出版日期:2012-06-28 发布日期:2014-12-03
通讯作者: 江泽飞,E-mail:jiangzf@hotmail.com
作者简介:钱六七,男,(1984-),硕士研究生,从事乳腺癌临床与基础的研究工作

Expression of circulating tumor cells in metastatic breast cancer patients and its relationship with multiple serum tumor markers

QIAN Liuqi¹,LIU Qian²,LIU Yi³,ZHANG Shaohua²,WANG Tao²,WU Shikai²,SONG Santai²,LIU Bing³,JIANG Zefei¹

1.Department of Breast Cancer,307 Clinic Institute,PLA,Anhui Medical University,Beijing 100071;
2.Department of Breast cancer,307 Hospital of PLA;
3.Department of Oncology,307 Hospital of PLA

Received:2012-02-03 Online:2012-06-28 Published:2014-12-03

摘要/Abstract

摘要： 目的探讨转移性乳腺癌的循环肿瘤细胞(CTC)和血清肿瘤标志物(CEA、CA153和CA125)的表达水平以及两者之间的相关性。方法采用CellSearch自动检测系统检测93例转移性乳腺癌患者开始新治疗前的循环肿瘤细胞(CTC),同时采用电化学发光法检测这些患者血清肿瘤标志物(CEA、CA153和CA125)的表达水平。结果 CTC阳性率为60%(56/93),与患者激素受体的状态、Her-2的状态、既往治疗的线数以及内脏转移无关。CEA的阳性率为56%(52/93),ER或PR阳性的患者CEA的阳性率更高(χ²=4.550,P=0.045),与Her-2的状态、既往治疗的线数以及内脏转移无关;CA153的阳性率为47%(44/93),与患者激素受体的状态、Her-2的状态、既往治疗的线数以及内脏转移无关;CA125的阳性率为41%(38/93);既往治疗大于等于二线的患者CA125的阳性率更高(χ²=4.501,P=0.038),与患者激素受体的状态、Her-2的状态以及是否有内脏转移无关。CTC和CEA之间呈正相关(r=0.296,P=0.004);CTC和CA153之间呈正相关(r=0.286,P=0.005);CTCs和CA125两者之间无相关性(r=0.184,P=0.077)。结论转移性乳腺癌患者的循环肿瘤细胞(CTC)检出率高,而且与血清肿瘤标志物(CEA和CA153)有明显相关性,提示联合检测转移性乳腺癌的循环肿瘤细胞(CTC)和血清肿瘤标志物(CEA和CA153)可能会对其治疗决策有所帮助,同时CTC有可能成为转移性乳腺癌新的治疗靶点。

Abstract: Objective To investigate the expression of circulating tumor cells in metastatic breast cancer and its relatonship with CEA,CA153 and CA125.Methods The Cell Search system was used to detect the expressions of CTCs before new line therapy,meanwhile the electrochemiluminescence was used to detect the expression of CEA,C153 and CA125 in 93 patients with metastatic breast cancer.Results 60%(56/93)metastatic breast cancer patients with ≥1 CTC/7.5mL at baseline.The CTC positivity was not correlated with hormone receptor status,Her-2 status,lines of previous treatment and visceral metastasis.The CEA positivity was 56%(52/93).It was associated with ER or PR-positive(χ²=4.550,P=0.045),and was not correlated with Her-2 status,lines of previous treatment and visceral metastasis.CA153 positivity was 47%(44/93).It was not correlated with hormone receptor status,Her-2 status,lines of previous treatment and visceral metastasis.CA125 positivity was 41%(38/93),and it was associated with over one-line previous treatment(χ²=4.501,P=0.038),However,CA125 positivity was not correlated with hormone receptor status,Her-2′s status and visceral metastasis.The CTC was positively correlated with CEA(r=0.296,P=0.004).It was positively correlated with CA153(r=0.286,P=0.005),and not correlated with CA125(r=0.184,P=0.077).Conclusion The circulating tumor cells(CTCs)positivity was high in patients with metastatic breast cancer,but also its positivity has correlation with CEA and CA153.Our study indicated that detection of circulating tumor cells combination with CEA and CA153 in metastatic breast cancer may be helpful for therapy,meanwhile the CTC may become a potential therapy target for metastatic breast cancer.

中图分类号:

R737.9

钱六七, 刘芊, 刘毅, 张少华, 王涛, 吴世凯, 宋三泰, 刘兵, 江泽飞. 循环肿瘤细胞在转移性乳腺癌中的表达及其与多种血清肿瘤标志物的关系[J]. 实用肿瘤学杂志, 2012, 26(3): 220-224.

QIAN Liuqi,LIU Qian,LIU Yi,ZHANG Shaohua,WANG Tao,WU Shikai,SONG Santai,LIU Bing,JIANG Zefei. Expression of circulating tumor cells in metastatic breast cancer patients and its relationship with multiple serum tumor markers[J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(3): 220-224.

[1]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[2]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[3]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[4]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[5]	白玉贤, 马仲娟, 苏颖玲, 慕安国, 谢蕊. 胃癌患者FHIT、hMLH1、p16、RAR-beta、Reprimo和TIMP3基因的甲基化研究[J]. 实用肿瘤学杂志, 2019, 33(1): 8-13.
[6]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.
[7]	何煦, 叶尚勉, 董丹丹, 李科. HLA-G在乳腺癌中的表达及意义[J]. 实用肿瘤学杂志, 2018, 32(5): 410-414.
[8]	王志, 刘忠卫, 曾雪芸, 隋明洁, 廖静怡, 李月欢, 黄卫东, 刘国祥. 基于EQ-5D-5L的结直肠癌癌前病变患者健康相关生命质量研究[J]. 实用肿瘤学杂志, 2018, 32(4): 320-326.
[9]	范宁宁, 耿敬姝. 长链非编码RNA MEG3在人胶质瘤细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(3): 219-223.
[10]	闫石, 霍明鸣, 庞慧, 李焱, 蔡莉. p53对绝经后HR阳性、HER-2阳性术后乳腺癌患者内分泌药物疗效的预测价值[J]. 实用肿瘤学杂志, 2018, 32(3): 234-213.
[11]	李林(综述), 李志高(审校). 二甲双胍与不同分子亚型乳腺癌的关系[J]. 实用肿瘤学杂志, 2018, 32(3): 267-270.
[12]	靳俊杰, 安静, 曹涤非, 宋爱利, 赵丽丽, 刘兆良. 组蛋白赖氨酸转移酶KAT6B基因shRNA慢病毒载体的构建与鉴定[J]. 实用肿瘤学杂志, 2018, 32(1): 1-6.
[13]	郑伟, 许守平, 庞达. 长链非编码RNA Linc00152在泛癌中表达、预后及功能研究[J]. 实用肿瘤学杂志, 2018, 32(1): 7-13.
[14]	殷玉莲, 张卫红, 周悦, 叶媚娜, 陈红风. ERα基因单核苷酸多态性与乳腺癌应用芳香化酶抑制剂引发骨丢失的相关性研究[J]. 实用肿瘤学杂志, 2018, 32(1): 14-18.
[15]	黎玉娇, 尚乃舰. 影像学评估乳腺癌新辅助化疗反应的研究进展[J]. 实用肿瘤学杂志, 2018, 32(1): 63-67.

循环肿瘤细胞在转移性乳腺癌中的表达及其与多种血清肿瘤标志物的关系

Expression of circulating tumor cells in metastatic breast cancer patients and its relationship with multiple serum tumor markers

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价